Wednesday, March 12, 2025 8:43:06 AM
https://fintel.io/i/m28-capital-management-lp
Top Increases This Quarter
We use the change in the portfolio allocation because this is the most meaningful metric. Changes can be due to trades or changes in share prices.
WVE / Wave Life Sciences Ltd. 5.66 70.07 68.7941 13.2486
TGTX / TG Therapeutics, Inc. 0.16 4.86 4.7756 0.6221
PRQR / ProQR Therapeutics N.V. 1.02 2.70 2.6525 0.6136
SWTX / SpringWorks Therapeutics, Inc. 0.11 3.99 3.9161 0.0293
almost 70% of M28 Capital is in WVE that is lead and advised John Maraganore, PhD. Alnylam Pharmaceuticals. Cambridge, MA. Brook ... M28 Capital Management.
$WVE
Top Increases This Quarter
We use the change in the portfolio allocation because this is the most meaningful metric. Changes can be due to trades or changes in share prices.
WVE / Wave Life Sciences Ltd. 5.66 70.07 68.7941 13.2486
TGTX / TG Therapeutics, Inc. 0.16 4.86 4.7756 0.6221
PRQR / ProQR Therapeutics N.V. 1.02 2.70 2.6525 0.6136
SWTX / SpringWorks Therapeutics, Inc. 0.11 3.99 3.9161 0.0293
almost 70% of M28 Capital is in WVE that is lead and advised John Maraganore, PhD. Alnylam Pharmaceuticals. Cambridge, MA. Brook ... M28 Capital Management.
$WVE
Bullish
Recent WVE News
- Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 • PR Newswire (US) • 05/19/2026 01:49:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 08:51:59 PM
- Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing • GlobeNewswire Inc. • 05/18/2026 08:30:00 PM
- Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference • GlobeNewswire Inc. • 05/13/2026 08:05:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/07/2026 08:01:18 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 05/01/2026 08:21:56 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:15:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/28/2026 11:50:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:34:43 AM
- Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/28/2026 11:30:00 AM
- Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/21/2026 09:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:49:30 PM
- Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States • GlobeNewswire Inc. • 04/21/2026 08:01:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/18/2026 01:00:05 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/18/2026 01:00:03 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/15/2026 08:13:46 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/15/2026 08:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 08:08:07 PM
- Wave Life Sciences Announces Proposed Redomiciliation to the United States • GlobeNewswire Inc. • 04/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 08:15:13 PM
- Wave Life Sciences shares plunge 30% despite encouraging obesity trial results • IH Market News • 03/26/2026 02:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 11:41:00 AM
- Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 • GlobeNewswire Inc. • 03/26/2026 11:30:00 AM
